Vitiligo Diagnosis: Wood’s Lamp, Dermoscopy, and Differential Workup
Key Takeaways Wood’s lamp: vitiligo shows bright chalk-white fluorescence with sharp borders; early lesions highlight margins before clinical contrast is […]
F-VASI
Excimer 308 nm in Vitiligo: Focal Therapy for Face/Neck and Acral Margins
Key Takeaways Targeted 308 nm is effective for limited facial/neck lesions and expanding edges of patches. Acral sites (hands/feet) respond slower;
NB-UVB 311 nm in Nonsegmental Vitiligo: Cohort Outcomes, Protocols, and Safety (n≈150–200)
Key Takeaways Backbone therapy for generalized/nonsegmental vitiligo with best responses on face/neck; acral lesions remain hardest. Typical schedules: 2–3×/week, incremental
Tofacitinib in Vitiligo: Case Series and Open-Label Studies ± NB-UVB
Key Takeaways Tofacitinib (JAK1/3 inhibitor) has shown facial repigmentation in multiple case series; responses improve with concurrent light (NB-UVB or
Ruxolitinib 1.5% Cream in Nonsegmental Vitiligo: TRuE-V2 Phase 3 Results
Key Takeaways TRuE-V2 confirmed facial repigmentation superiority of ruxolitinib 1.5% cream versus vehicle at ~24 weeks, mirroring TRuE-V1. Continued treatment
Ruxolitinib 1.5% Cream in Nonsegmental Vitiligo: TRuE-V1 Phase 3 Results
Key Takeaways In TRuE-V1, topical ruxolitinib 1.5% cream showed clinically meaningful facial repigmentation versus vehicle by week 24, with continued
Pimecrolimus 1% vs Placebo for Facial Vitiligo: Randomized Controlled Trial Overview
Key Takeaways For facial vitiligo, pimecrolimus 1% shows superiority over placebo on F-VASI and global assessments in several RCTs/split-face designs.
NB-UVB + Tacrolimus vs NB-UVB Alone in Vitiligo: Randomized Controlled Trial
Key Takeaways Adding topical tacrolimus to NB-UVB is associated with higher facial response rates and earlier perifollicular repigmentation in many
NB-UVB 311 nm vs PUVA in Vitiligo: Comparative Efficacy and Safety
Key Takeaways NB-UVB achieves comparable or superior facial repigmentation versus PUVA in multiple comparative studies, with fewer systemic adverse effects.